Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn Acquires 125,791 Shares

Generation Bio Co. (NASDAQ:GBIO) Director Anthony G. Quinn acquired 125,791 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were acquired at an average price of $0.96 per share, for a total transaction of $120,759.36. Following the acquisition, the director now directly owns 214,286 shares in the company, valued at $205,714.56. This represents a 142.14 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Generation Bio Stock Performance

NASDAQ GBIO opened at $0.88 on Wednesday. The stock has a market capitalization of $58.78 million, a price-to-earnings ratio of -0.40 and a beta of 2.72. The stock’s 50 day moving average price is $1.35 and its two-hundred day moving average price is $2.13. Generation Bio Co. has a 52 week low of $0.75 and a 52 week high of $4.65.

Institutional Investors Weigh In On Generation Bio

Several institutional investors have recently bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of Generation Bio by 7.4% during the 2nd quarter. Rhumbline Advisers now owns 78,903 shares of the company’s stock worth $222,000 after purchasing an additional 5,430 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Generation Bio by 2.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock worth $1,046,000 after purchasing an additional 8,692 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Generation Bio by 91.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock worth $54,000 after purchasing an additional 9,075 shares in the last quarter. State Street Corp raised its stake in shares of Generation Bio by 1.2% during the 3rd quarter. State Street Corp now owns 992,188 shares of the company’s stock worth $2,451,000 after purchasing an additional 11,669 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Generation Bio by 8.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 164,573 shares of the company’s stock worth $464,000 after purchasing an additional 13,104 shares in the last quarter. Institutional investors own 95.22% of the company’s stock.

Analyst Upgrades and Downgrades

GBIO has been the topic of several recent analyst reports. Wedbush reiterated an “outperform” rating and set a $5.00 price objective on shares of Generation Bio in a report on Thursday, November 7th. Needham & Company LLC cut their target price on Generation Bio from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.